Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) is focused on commercializing patent-protected disruptive healthcare technologies specifically designed to take leading roles for the treatment of a broad array of chronic, debilitating and life-threatening diseases including respiratory, autoimmune and cancer indications. The company anticipates building significant value for its shareholders while meeting its objectives. For further information, visit the Company’s web site at www.accentia.net.
- 17 years ago
QualityStocks
Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Pelican Acquisition Corp. (NASDAQ: PELI) Approves Business Combination With Greenland Exploration And Pelican Holdco
Pelican Acquisition (NASDAQ: PELI) announced that shareholders approved its proposed business combination with Pelican Holdco…
-
QualityStocksNewsBreaks – ParaZero Technologies Ltd. (NASDAQ: PRZO) Signs Strategic Cooperation Agreement With BonV Aero To Expand Counter-UAS Presence In India
ParaZero Technologies (NASDAQ: PRZO) announced the signing of a strategic cooperation agreement with India-based BonV…
-
QualityStocksNewsBreaks – Black Hawk Acquisition Corporation (Nasdaq: BKHA) SPAC Target Vesicor Therapeutics Names Michael Tolentino CEO
Black Hawk Acquisition (Nasdaq: BKHA, BKHAU, BKHAR) announced that its proposed de-SPAC acquisition target, Vesicor Therapeutics Inc., has…